Hypothesis

We propose that intracellular NAD+ concentration acts as a metabolic gatekeeper that determines whether a cell can successfully undergo OSK‑driven partial reprogramming. When NAD+ falls below a tissue‑specific threshold, sirtuin activity and PARP‑mediated DNA repair become limiting, causing the chromatin landscape to resist the epigenetic resetting imposed by OSK factors. Consequently, reprogramming efficiency—and the ensuing functional benefits—scale with NAD+ levels, and boosting NAD+ prior to or during OSK pulses should lower the effective dose and shorten the exposure time needed to achieve a youthful methylome.

Mechanistic Rationale

• Sirtuin‑dependent chromatin remodeling: SIRT1 and SIRT6 deacetylate histones and transcription factors, facilitating the opening of repressed loci that OSK factors target. NAD+‑dependent sirtuin activity has been shown to enhance the accessibility of pluripotency‑associated promoters in fibroblasts 1.
• PARP competition for NAD+: In aged cells, DNA damage elevates PARP consumption, sequestering NAD+ away from sirtuins. This shifts the NAD+ budget toward repair at the expense of epigenetic modulation, creating a bistable state where high PARP activity locks chromatin in an aged configuration despite OSK presence 2.
• Metabolic sensing via HIF‑1α: Low NAD+ stabilizes HIF‑1α, which recruits HDACs to promoters of genes involved in mitochondrial biogenesis, reinforcing a hypometabolic state that antagonizes the proliferative‑like signaling required for early reprogramming events 3.

Together, these mechanisms suggest that NAD+ does not merely fuel metabolism; it directly influences the epigenetic permissiveness window opened by OSK factors.

Testable Predictions

1. Dose‑response relationship: In aged murine hepatocytes, graded NAD+ supplementation (via NR or NMN) before a fixed 4‑day OSK pulse will produce a linear increase in H3K27ac accumulation at OSK target enhancers, measurable by CUT&Tag, and a corresponding decrease in epigenetic age as gauged by the mouse Horvath clock.
2. Threshold effect: Cells with NAD+ levels below 30 % of young adult baseline will fail to reduce p16^INK4a expression despite OSK exposure, whereas those above this threshold will show ≥50 % repression, establishing a quantifiable NAD+ cutoff for reprogramming competence.
3. Closed‑loop validation: Real‑time nanopore methylation profiling (48‑hour turnaround) combined with intermittent NAD+ biosensing (fluorescent Peredox sensor) will enable adaptive OSK dosing: when NAD+ rises above the threshold, the OSK pulse length shortens, achieving comparable methylome reset with 40 % less doxycycline exposure compared to fixed schedules.

Experimental Design

• Model: C57BL/6J mice aged 24 months, with liver‑specific inducible OSK (AAV8‑TRE‑OSK) and a NAD+ biosensor transgene (AAV8‑PEREDOX).
• Groups: (a) OSK only (standard 4‑day pulse every 2 weeks), (b) OSK + NR (400 mg/kg/day) initiated 48 h before each pulse, (c) OSK + NR with adaptive dosing guided by NAD+ sensor read‑out (pulse stops when NAD+ > threshold).
• Readouts: Liver epigenome (methylation arrays), fibrosis markers (α‑SMA, collagen I), functional assays (serum ALT/AST, glycogen stores), and tumorigenicity monitoring over 6 months.

Falsifiability

If NAD+ supplementation fails to shift the OSK dose‑response curve, or if adaptive dosing guided by NAD+ sensing does not reduce total OSK exposure while achieving equivalent epigenetic rejuvenation, the hypothesis would be refuted. Conversely, a demonstrable NAD+‑dependent modulation of reprogramming efficiency would support the view that NAD+ decline reflects a metabolic budgeting decision rather than a passive downstream consequence of aging.

Implications

Linking NAD+ status to OSK efficacy provides a mechanistic bridge between the "budget cut" metaphor of NAD+ decline and the practical need for personalized, feedback‑driven reprogramming therapies. It suggests that restoring the cell’s perceived future worth—by replenishing its NAD+ budget—may be a prerequisite for epigenetic youth restoration, not merely a parallel anti‑aging strategy.